Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.53% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences, Inc. is a commercial-stage medical device company dedicated to developing and delivering innovative therapies for liver and pancreatic tumors. While specifics on its founding year are not readily available in the public domain, the company has emerged as a player in regional cancer therapies.
Core Business Areas
- Regional Cancer Therapies: Focuses on developing and commercializing devices for regional cancer therapies, including drug-eluting systems and pressure-enabled drug delivery.
Leadership and Structure
Information about the leadership team and organizational structure can be found on their investor relations section of their website.
Top Products and Market Share
Key Offerings
- TriNav Microcatheter: A microcatheter designed for targeted delivery of therapeutics to liver tumors. Market share data is not readily available. Key competitors include Boston Scientific and Terumo.
- PULSE Duet Adaptive Pressure System: A pressure-enabled drug delivery system designed to enhance the penetration and distribution of therapeutics in solid tumors. Market share data is not readily available. Key competitors include Merit Medical Systems and Medtronic.
Market Dynamics
Industry Overview
The medical device industry, specifically in cancer therapies, is experiencing growth driven by advancements in technology and increasing prevalence of cancer. The demand for targeted drug delivery systems is rising.
Positioning
TriSalus is positioned as an innovator in regional cancer therapies, particularly in pressure-enabled drug delivery. Their competitive advantage lies in their proprietary technologies.
Total Addressable Market (TAM)
The TAM for regional cancer therapies is estimated to be in the billions of dollars. TriSalus is aiming to capture a significant share of this market with its innovative technologies.
Upturn SWOT Analysis
Strengths
- Proprietary Pressure-Enabled Drug Delivery Technology
- Focus on Difficult-to-Treat Liver and Pancreatic Tumors
- Commercial-Stage Company with Approved Products
Weaknesses
- Limited Market Share Compared to Larger Competitors
- Reliance on Specific Technologies
- Requires regulatory approvals
Opportunities
- Expanding into New Geographies
- Developing New Applications for Pressure-Enabled Drug Delivery
- Partnerships with Pharmaceutical Companies
Threats
- Competition from Established Medical Device Companies
- Technological Advancements by Competitors
- Changes in Regulatory Environment
Competitors and Market Share
Key Competitors
- BSX
- MDT
- MRMD
Competitive Landscape
TriSalus competes with larger, more established medical device companies. They aim to differentiate themselves with their pressure-enabled drug delivery technology. Gaining market share is a key challenge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's relatively recent entry into the market.
Future Projections: Future growth projections depend on the success of their technologies and market adoption.
Recent Initiatives: Focusing on clinical trials to establish product efficacy and market penetration efforts.
Summary
TriSalus Life Sciences is a relatively new company focusing on innovative drug delivery systems for liver and pancreatic tumors, but it needs to improve market position by differentiating itself further as it faces bigger players in the competitive landscape. Success depends on clinical trial results, market adoption, and strategic partnerships. Its strengths lie in its proprietary technology, while its weaknesses include limited market share. Threats from larger companies and a changing regulatory landscape should be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- TriSalus Life Sciences Inc. Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data and financial performance data are based on available information and estimates. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.